Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Leerink notes Eli Lilly (LLY) terminated its volenrelaxin CKD due to failure of a “related heart failure study,” which has caused significant ...